Expression profiling and identification of conserved candidates.
Generation, quantification and analysis of proteome data. Information. S8: Sequence information of CRISPLD1-iPSC-KO. Table S3 : Antibodies used in this study. Table S4 : qPCR primer used in this study.
Supplementary data Excel files:
Data file S1: Human mRNA expression profiles 
Supplementary methods
Expression profiling and identification of conserved candidates. Differential expression (DE) was assessed for the CH/1wTAC and HF group compared to the control/sham group.
Differential expression analysis was done using DESeq2. Initial DE analysis of the control transcriptomes vs pathology (cut offs: minimal counts > 10, log2FC >+/-1, adjusted p value < 0.05) resulted in a list of significant DEGs for each of the conditions vs. the control. Each gene that were significantly differentially expressed in at least one DE analysis was analyzed for expression in the other condition and the control comparing the normalized counts (see data file S2 and S3) using the following criteria:
If the sum of two pathology groups were higher than 20 counts the medians were calculated.
Fold changes higher than 1.5 received negative or positive labels depending on the expression between the 3 conditions. Fold changes below 1.2 indicate no alteration of expression between conditions. Exclusive expression is given by expression higher than 50 counts in one case and less than 10 counts in the other two. Data sets of human and mouse genes were compared under consideration of the expression profiles and 25 genes were identified showing conserved changes in expression during disease progression in human and mouse.
Generation, quantification and analysis of proteome data. For generation of a peptide library, equal amount aliquots from each sample were pooled to a total amount of 80 µg, and separated into eight fractions using a reversed phase spin column (Pierce High pH Reversed-Phase Peptide Fractionation Kit, Thermo Fisher Scientific). All samples were spiked with a synthetic peptide standard used for retention time alignment (iRT Standard, Schlieren, Schweiz).
Protein digests were analyzed on a nanoflow chromatography system (Eksigent nanoLC425) hyphenated to a hybrid triple quadrupole-TOF mass spectrometer (TripleTOF 5600+) equipped with a Nanospray III ion source (Ionspray Voltage 2400 V, Interface Heater Temperature 150°C, Sheath Gas Setting 12) and controlled by Analyst TF 1.7.1 software build 1163 (all AB Sciex). In brief, peptides were dissolved in loading buffer (1% acetonitrile, 0.1% Trifluoroacetic acid in water) to a concentration of 0.3 µg/µl. For each analysis 1.5 µg of digested protein were enriched on a µPAC Trapping column (micro-Chip Based Seperations, Symmetry C18, Pharma Fluidics) and separated on an analytical RP-C18 column (50cm µPAC RP C18, PharmaFluidics) using a 60 min linear gradient of 5-35 % acetonitrile/0.1% formic acid (v:v) at 300 nl min -1 .
Qualitative LC/MS/MS analysis was performed using a Top20 data-dependent acquisition method with an MS survey scan of m/z 350-1250 accumulated for 350 ms at a resolution of 30,000 full width at half maximum (FWHM). MS/MS scans of m/z 180-1600 were accumulated for 100 ms at a resolution of 17,500 FWHM and a precursor isolation width of 0.7 FWHM, resulting in a total cycle time of 2.9 s. Precursors above a threshold MS intensity of 125 cps with charge states 2+, 3+, and 4+ were selected for MS/MS, the dynamic exclusion time was set to 30 s. MS/MS activation was achieved by CID using nitrogen as a collision gas and the manufacturer's default rolling collision energy settings. Two technical replicates per reversed phase fraction were analyzed to construct a spectral library. Spectral library generation and SWATH peak extraction were achieved in PeakView Software version 2.1 build 11041 (AB Sciex) using the SWATH quantitation microApp version 2.0 build 2003. Following retention time correction using the iRT standard, peak areas were extracted using information from the MS/MS library at an FDR of 1% [15] . The resulting peak areas were then summed to peptide and finally protein area values, which were used for further statistical analysis.
Supplementary figures
Supplementary figure S1: Echocardiographic analysis of sham and TAC mice. 
Supplementary information S8: Sequence information of CRISPLD1-iPSC-KO.
CRISPLD1-iPSC-KO-DNA, mRNA and protein sequence after CRISPR/Cas9 mediated deletion. Deletion: 34 bp  CTCTATAATAAATTATATGAATGTCTTAAATCTATACGCCAAAATAATTA  CTTAGAATGTTCATATATAGTGATGTTTCACAATGTTTTATAAATTATGC  CATTAGACTACTTTTTAATAGAGCGTATCATCTCTTAAAGGGGAAACTGG  TGGGGCCATGCCCCTTACAAACATGGGCGGCCCTGTTCTGCTTGCCCACC  TAGTTTTGGAGGGGGCTGTAGAGAAAATCTGTGCTACAAAGGTAAGTGCT  ATTGTGTTGTGGTATTCATGTTGATTTATATTTTAATCCAGCTCCTGCAT  TACTTATGTTTAAAAAAGCCAGAAGTGCACTTAATGATCACACGAAAAGT  ATCTAGAACTCTATTTCAAATATTTTGAAGAAATCTTTTACAAATATTTA  TATTACTAATAAGTTTGTTATATGAAATTTTTAAAGTTCCATGGTTATTT  CAGGTAACTATTTCTGATTCTACTTTGAAATTACCCCAGAATGACAAGTA  TATTTATATTCTTAAAAAGAGTCATCTTGATGTATGGTTGACTAGAGTTA  TTTCCATAACTGTCATCTTTTTTTAAAGGATTTAGCAATTTAACACAATT  TATTTTTAGCGCTTTAAACATTTTTAACAAAATACCCCTTTGTGTATCTT  ATTGAACCATGCTCAATGAATTATGTTGATTTTTCACTTCTCACTGCACA  CTATTCAATTTGTCATGCTAAAATAATAAGAAAAGTATAATAGTAACATA  AAACTACTATAAAAGTAGTACTGTCAAATGCATTTGATATCTTAAAAAGT  AAATATGGTGTCCTGTTTATAGCACATAAAGATAAACTGTTATGACAAAG  CTTTGTGAAAAGTCATGCACTTGTGCATTCAAGTGAACATTTTTTACTGC  CTTGTACTTTTTTCTTGATGACTAAAAGAGGAATAATGTAGACGAAGTGT  ATTAGGAAATATTTGAACAATTGCAGCCCTTTTTTAGTGCTCATAATGAC  ACGTGTCTTTTTTTCCCTTAATGATGCATTAACTAAAATGAGTAGACAAG  AAGTGCCCATATATGTCCCTCTGTTGTGTAAGCCATTTTAAAATTCCTAG  AAGCGTTTGCAGCATTTTTTCCTTGTGTGGGTGTTTTTCATATTCTCTGT  GTCCAAACCTCCAACCTACCTGCCTCTTCCCCGGTGACCATTATCTTTTA  CTTAAAGCTGACTTTCTTGTGACTTCATACTTTTTTTTTAGGTTCTGAGT  TCTTGGGCATGCATCAAAATTATACACCTCTCCAAAATGTGCCATTGTCA  AGCCTTTGATAAAGGCCAGTCTGGAAATAAACATTAAATTCAAAGTTTGA  AATTACTCTCCATACTCAAGTTTAAATTTCTGCATATTGAATTTTCTTCT  AAAGGAAAAAAACTCTATGGACATGGATTTTGTCATAAATAATAAGGGCA  TGTAAATCCTTCTTTAGGCCACATTTCCATTTGGGAGAAGTCTAAATGTG  ATCCTCCTGAAAATATTAAGAATATGATTTTAATTGAAAACAAATTTGAT  TTTGCTAAGCCATGACCTTATTAGATCACTGTGTAGATTTCATGGTGTCA  TTATGAAAATCAAACAATGATATGTTGAAATATAAGCAAAGTTTAGAAGT  GGCTTCATTGAATATTAGTCGAACATTAACATAAATGAATCAAGGACTTA  AAGGCTTATGTGTGTTCATTTATTCCACTGCAGTACCTAAGATCACCACC  TTAAGCCAAAACCTGTGCAGAAAAACAGTACTGATTTTTCTAGTTCTAAA  TGTTAAATAGGAGTATTAAAGTATATTATTATTTGATAATTCATGCACAT  GTAAAATAGGGTTAATATTTCCTAAATCTGCTTTCTCTAACAGAAGGGTC 
ipWT1.3 CRISPLD1 iPSC KO genomic sequence
AGACAGGTATTATCCCCCTCGAGAAGAGGAAACAAATGAAATAGAAC--- -------------------------------GACAAGATCAGATGATAGT AGCAGAAATGAAGTCATAAGCGCACAGCAAATGTGTAAGACCTCCATATT ACTTATAAAAATTTTCAAAGTACATAAATGGTATATCCATCAAGATTTTA TTAATTTGAACATTTTTAGAATGGAAAAAATTTTGTCATTAGGCTATATA TAATGAACTACAACTGCTTTTATATTATTTAAGTTATTTAGGTATTTTTT
B3 mRNA Validation -> Exon 6 to 8 is spliced out (303 bp)
1 ATGAAGTGTA CCGCGCGGGA GTGGCTCAGA GTAACCACAG TGCTGTTCAT 51 GGCTAGAGCA ATTCCAGCCA TGGTGGTTCC CAATGCCACT TTATTGGAGA 101 AACTTTTGGA AAAATACATG GATGAGGATG GTGAGTGGTG GATAGCCAAA 151 CAACGAGGGA AAAGGGCCAT CACAGACAAT GACATGCAGA GTATTTTGGA 201 CCTTCATAAT AAATTACGAA GTCAGGTGTA TCCAACAGCC TCTAATATGG 251 AGTATATGAC ATGGGATGTA GAGCTGGAAA GATCTGCAGA ATCCTGGGCT 301 GAAAGTTGCT TGTGGGAACA TGGACCTGCA AGCTTGCTTC CATCAATTGG 351 ACAGAATTTG GGAGCACACT GGGGAAGATA TAGGCCCCCG ACGTTTCATG 401 TACAATCGTG GTATGATGAA GTGAAAGACT TTAGCTACCC ATATGAACAT 451 GAATGCAACC CATATTGTCC ATTCAGGTGT TCTGGCCCTG TATGTACACA 501 TTATACACAG GTCGTGTGGG CAACTAGTAA CAGAATCGGT TGTGCCATTA 551 ATTTGTGTCA TAACATGAAC ATCTGGGGGC AGATATGGCC CAAAGCTGTC 601 TACCTGGTGT GCAATTACTC CCCAAA------------------------ G TACGAATGTC CTGCTGGCTG  951 TTTGGATAGT AAAGCTAAAG TTATTGGCAG TGTACATTAT GAAATGCAAT  1001 CCAGCATCTG TAGAGCTGCA ATTCATTATG GTATAATAGA CAATGATGGT  1051 GGCTGGGTAG ATATCACTAG ACAAGGAAGA AAGCATTATT TCATCAAGTC  1101 CAATAGAAAT GGTATTCAAA CAATTGGCAA ATATCAGTCT GCTAATTCCT  1151 TCACAGTCTC TAAAGTAACA GTTCAGGCTG TGACTTGTGA AACAACTGTG  1201 GAACAGCTCT GTCCATTTCA TAAGCCTGCT TCACATTGCC CAAGAGTATA  1251 CTGTCCTCGT AACTGTATGC AAGCAAATCC ACATTATGCT CGTGTAATTG  1301 GAACTCGAGT TTATTCTGAT CTGTCCAGTA TCTGCAGAGC AGCAGTACAT  1351 GCTGGAGTGG TTCGAAATCA CGGTGGTTAT GTTGATGTAA TGCCTGTGGA  1401 CAAAAGAAAG ACCTACATTG CTTCTTTTCA GAATGGAATC TTCTCAGAAA  1451 GTTTACAGAA TCCTCCAGGA GGAAAGGCAT TCAGAGTGTT TGCTGTTGTG  1501 Given is the regulation in the transition to failure, the gene symbol and name, whether it is found to be described in compensated hypertrophy (CH) and heart failure (HF) in the existing literature and the related publication. Supplementary table 4 : List of qPCR primers used in this study. Given is the primer name, company name (if purchased, own refers to self designed primers) and the primer sequence or order number if purchased.
RT-PCR primers Company Sequence or order#
HsMYH6-FW-1 own GTCAAAGCCAAGATTTTGTCCC 
